Austrian biotech company Themis Bioscience said on Tuesday it had started a clinical trial of an experimental Zika vaccine in healthy volunteers, opening up another front in the race to prevent the spread of the mosquito-borne disease.
Themis’s product, which is based on measles immunization technology, is the first vaccine containing attenuated, or weakened, live virus to reach the human testing phase.
Source: Reuters
Filed Under: Drug Discovery
